Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Frontiers in Public Health|April 6, 2019
Vaccine Production in Africa: A Feasible Business Model for Capacity Building and Sustainable New Vaccine IntroductionGeofrey Makenga, Stefano Bonoli, Emanuele Montomoli, et al.
Frontiers in Microbiology|November 25, 2022
Enrichment of antibiotic resistance genes within bacteriophage populations in saliva samples from individuals undergoing oral antibiotic treatmentsTilde Andersson, Geofrey Makenga, Filbert Francis, et al.
Trials|March 24, 2018
Multiple-level stakeholder engagement in malaria clinical trials: addressing the challenges of conducting clinical research in resource-limited settingsGeorge Mtove, Joshua Kimani, William Kisinza, et al.
Microorganisms|October 28, 2023
Unveiling Rare Pathogens and Antibiotic Resistance in Tanzanian Cholera Outbreak WatersVito Baraka, Tilde Andersson, Geofrey Makenga, et al.
Plos One|January 30, 2025
The impact of intermittent preventive treatment in school aged children with dihydroartemisinin piperaquine and artesunate amodiaquine on IgG response against six blood stage Plasmodium falciparum antigensEric Lyimo, Geofrey Makenga, Louise Turner, et al.
Parasite Epidemiology and Control|November 4, 2020
Prevalence of malaria parasitaemia in school-aged children and pregnant women in endemic settings of sub-Saharan Africa: A systematic review and meta-analysisGeofrey Makenga, Sonia Menon, Vito Baraka, et al.
Frontiers in Immunology|July 5, 2021
Immunogenicity and Efficacy of Pneumococcal Conjugate Vaccine (Prevenar13®) in Preventing Acquisition of Carriage of Pneumococcal Vaccine Serotypes in Tanzanian Children With HIV/AIDSGeofrey Makenga, George Mtove, J Kevin Yin, et al.
Contemporary Clinical Trials Communications|May 9, 2020
Effectiveness and safety of intermittent preventive treatment for malaria using either dihydroartemisinin-piperaquine or artesunate-amodiaquine in reducing malaria related morbidities and improving cognitive ability in school-aged children in Tanzania: A study protocol for a controlled randomised trialGeofrey Makenga, Vito Baraka, Filbert Francis, et al.
The Lancet. Global Health|July 20, 2023
Effectiveness and safety of intermittent preventive treatment with dihydroartemisinin-piperaquine or artesunate-amodiaquine for reducing malaria and related morbidities in schoolchildren in Tanzania: a randomised controlled trialGeofrey Makenga, Vito Baraka, Filbert Francis, et al.
BMC Public Health|August 13, 2025
Malaria-malnutrition interaction: prevalence, risk factors, and the impact of intermittent preventive therapy for malaria on nutritional status of school-age children in Muheza, Tanga, Tanzania - A cross-sectional survey and a randomized controlled open-label trialJeremiah John Hhera, Geofrey Makenga, Vito Baraka, et al.
Pageof 3